Sellas Life Sciences Group Inc (SLS) said after close Thursday that it lost $0.33 per share in quarter three 2023.
On the revenue line, the company reported $0.00, missing estimates by $8.7 million.
In the same quarter a year ago, the company lost $0.34 per share on revenue of $0.00.
The stock is down 0.01% to $0.91 after the report.
The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.
The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.
InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.
Sellas Life Sciences Group Inc has performed poorly during the past few months, garnering a low Long-Term Technical Rank by InvestorsObserver of 3, putting Sellas Life Sciences Group Inc in the bottom 25% of stocks. The firm was recently trading at a 52-week low of $0.81 on November 9, 2023 and set a 52-week high on November 10, 2022 at $5.23.
SELLAS Life Sciences Group Inc is a biopharmaceutical company. The company is engaged in the development of novel cancer immunotherapies for a broad range of cancer indications. Its pipeline products are Galinpepimut-S, Nelipepimut-S, GALE-301/-302 and NeuVax.
News Home
Sellas Life Sciences Group Inc Down 0.01% To $0.91 After Earnings
Mentioned in this article
